NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis → Urgent new message from Porter Stansberry (From Porter & Company) (Ad) Free BNTX Stock Alerts $92.99 +0.51 (+0.55%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$91.65▼$94.0250-Day Range$88.96▼$111.8852-Week Range$87.90▼$136.91Volume441,922 shsAverage Volume663,250 shsMarket Capitalization$22.10 billionP/E Ratio8.07Dividend YieldN/APrice Target$142.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioNTech alerts: Email Address BioNTech MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside53.5% Upside$142.71 Price TargetShort InterestHealthy1.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $4.81 to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector328th out of 947 stocksBiological Products, Except Diagnostic Industry46th out of 159 stocks 4.2 Analyst's Opinion Consensus RatingBioNTech has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $142.71, BioNTech has a forecasted upside of 53.5% from its current price of $92.99.Amount of Analyst CoverageBioNTech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.23% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in BioNTech has recently decreased by 2.99%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTX. Previous Next 2.4 News and Social Media Coverage News SentimentBioNTech has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for BioNTech this week, compared to 8 articles on an average week.Search Interest41 people have searched for BNTX on MarketBeat in the last 30 days. This is an increase of 37% compared to the previous 30 days.MarketBeat FollowsOnly 45 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have not sold or bought any company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.52% of the stock of BioNTech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioNTech are expected to decrease in the coming year, from $4.81 to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is 8.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 152.59.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is 8.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 226.35.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About BioNTech Stock (NASDAQ:BNTX)BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Read More BNTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTX Stock News HeadlinesMarch 16, 2024 | ca.finance.yahoo.comBNTX Apr 2024 87.500 callMarch 15, 2024 | 247wallst.comThis Biotech Stock Plunged 20% but Wall Street Expects a 195% RecoveryMarch 19, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: March 15, 2024 | ca.finance.yahoo.comBNTX Mar 2024 50.000 callMarch 14, 2024 | nasdaq.comJune 2025 Options Now Available For BioNTech (BNTX)March 13, 2024 | americanbankingnews.comBioNTech (BNTX) Scheduled to Post Quarterly Earnings on WednesdayMarch 12, 2024 | stockhouse.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioNTechMarch 12, 2024 | prnewswire.comBNTX DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action - BNTXMarch 19, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 11, 2024 | finanznachrichten.deBioNTech SE: BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024March 11, 2024 | wsj.comModerna, BioNTech Stocks Rise on New mRNA PossibilitiesMarch 11, 2024 | stockhouse.comDEADLINE TOMORROW: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the FirmMarch 11, 2024 | markets.businessinsider.comDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioNTechMarch 11, 2024 | finance.yahoo.comWill Weakness in BioNTech SE's (NASDAQ:BNTX) Stock Prove Temporary Given Strong Fundamentals?March 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTXMarch 11, 2024 | globenewswire.comBioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024March 11, 2024 | prnewswire.comThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit - BNTXMarch 10, 2024 | markets.businessinsider.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioNTechMarch 9, 2024 | sg.finance.yahoo.comBNTX Dec 2025 55.000 callMarch 9, 2024 | sg.finance.yahoo.comBNTX Dec 2025 55.000 putMarch 9, 2024 | msn.comHere's Why Artisan Mid Cap Fund Harvested BioNTech SE (BNTX)March 8, 2024 | finance.yahoo.comHere’s Why Artisan Mid Cap Fund Harvested BioNTech SE (BNTX)March 7, 2024 | msn.comFDA experts recommend changes to flu shotsMarch 7, 2024 | prnewswire.comKessler Topaz Meltzer & Check, LLP Reminds BioNTech SE Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the FirmMarch 7, 2024 | finanznachrichten.deBioNTech SE: BioNTech Announces Planned Retirement of Sean MarettMarch 7, 2024 | globenewswire.comBioNTech Announces Planned Retirement of Sean MarettMarch 6, 2024 | stockhouse.comBioNTech Shareholder NoticeSee More Headlines Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today3/18/2024Next Earnings (Confirmed)3/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BNTX CUSIPN/A CIK1776985 Webwww.biontech.de Phone49-61-31908-40Fax49-6131-908-4390Employees4,530Year Founded2008Price Target and Rating Average Stock Price Target$142.71 High Stock Price Target$260.00 Low Stock Price Target$99.00 Potential Upside/Downside+53.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)$11.53 Trailing P/E Ratio8.07 Forward P/E Ratio19.33 P/E GrowthN/ANet Income$9.94 billion Net Margins41.09% Pretax Margin52.86% Return on Equity13.15% Return on Assets11.73% Debt Debt-to-Equity Ratio0.01 Current Ratio10.38 Quick Ratio10.14 Sales & Book Value Annual Sales$18.24 billion Price / Sales1.21 Cash Flow$41.51 per share Price / Cash Flow2.24 Book Value$87.07 per share Price / Book1.07Miscellaneous Outstanding Shares237,710,000Free Float192,074,000Market Cap$22.10 billion OptionableOptionable Beta0.23 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ozlem Tureci M.D. (Age 57)Co-Founder, Chief Medical Officer & Member of Management Board Comp: $895.64kMr. Jens H. Holstein (Age 61)CFO & Member of Management Board Comp: $943.18kDr. Sierk Poetting Ph.D. (Age 51)MD, COO & Member of Management Board Comp: $990.72kMr. Ryan Richardson (Age 45)Chief Strategy Officer, MD & Member of Management Board Comp: $478.61kMr. Sean Marett (Age 59)Chief Business Officer, Chief Commercial Officer & Member of Management Board Comp: $918.33kDr. James Timothy Patrick Ryan Ph.D. (Age 49)Chief Legal Officer & Member of the Management Board Mr. Zach TaylorSenior Vice President of Corporate Development & StrategyDr. Oliver Henning Ph.D.Senior Vice President of OperationsDr. Sebastian Kreiter M.D.Senior Vice President of Immunotherapy & Preclinical ResearchMr. Siegbert KloosSenior Vice President of Global R&D Digital, Datand InformaticsMore ExecutivesKey CompetitorsargenxNASDAQ:ARGXNeurocrine BiosciencesNASDAQ:NBIXBiogenNASDAQ:BIIBBio-TechneNASDAQ:TECHRepligenNASDAQ:RGENView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 26,777 shares on 3/1/2024Ownership: 0.077%Investmentaktiengesellschaft Fuer Langfristige Investoren TGVBought 3,000 shares on 3/1/2024Ownership: 0.006%Quintet Private Bank Europe S.A.Sold 440 shares on 2/29/2024Ownership: 0.000%Virtu Financial LLCBought 2,600 shares on 2/26/2024Ownership: 0.001%Price T Rowe Associates Inc. MDBought 1,544 shares on 2/16/2024Ownership: 0.026%View All Institutional Transactions Should I Buy BioNTech Stock? BNTX Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BioNTech was last updated on Sunday, March 17, 2024 at 4:19 PM. Pros Here are some ways that investors could benefit from investing in BioNTech SE: BioNTech is actively developing immunotherapies for cancer and infectious diseases, showing a commitment to addressing critical health issues. The company has a strong pipeline of product candidates, including BNT111 for advanced melanoma and BNT113 for HPV 16+ head and neck cancers, indicating potential for future growth. With a current ratio of 10.38 and a quick ratio of 10.14, BioNTech demonstrates strong liquidity and ability to meet short-term obligations. Despite recent fluctuations, BioNTech's stock price has shown resilience, with a 50-day moving average of $95.82, suggesting stability in the market. BioNTech's innovative approach to developing FixVac products, such as BNT116 for non-small cell lung cancer, showcases the company's dedication to cutting-edge research and development. Cons Investors should be bearish about investing in BioNTech SE for these reasons: Market volatility and uncertainties in the biotechnology sector could impact BioNTech's stock performance, leading to potential risks for investors. With a PE ratio of 8.02 and a beta of 0.23, BioNTech's stock valuation and sensitivity to market movements may pose challenges for investors seeking stable returns. The company's 1-year low of $87.90 indicates past price fluctuations that could affect investor confidence in the stock's long-term performance. While BioNTech has a debt-to-equity ratio of 0.01, indicating low debt levels, investors should consider the impact of any future debt obligations on the company's financial health. External factors, such as regulatory changes or competitive pressures in the biotechnology industry, could influence BioNTech's growth prospects and stock price in the future. BNTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioNTech stock right now? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares. View BNTX analyst ratings or view top-rated stocks. What is BioNTech's stock price target for 2024? 12 Wall Street research analysts have issued 1 year price targets for BioNTech's stock. Their BNTX share price targets range from $99.00 to $260.00. On average, they predict the company's share price to reach $142.71 in the next year. This suggests a possible upside of 53.5% from the stock's current price. View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts. How have BNTX shares performed in 2024? BioNTech's stock was trading at $105.54 at the start of the year. Since then, BNTX stock has decreased by 11.9% and is now trading at $92.99. View the best growth stocks for 2024 here. When is BioNTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our BNTX earnings forecast. How can I listen to BioNTech's earnings call? BioNTech will be holding an earnings conference call on Wednesday, March 20th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were BioNTech's earnings last quarter? BioNTech SE (NASDAQ:BNTX) issued its earnings results on Monday, November, 6th. The company reported $0.67 EPS for the quarter, topping the consensus estimate of ($0.59) by $1.26. The business earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million. BioNTech had a trailing twelve-month return on equity of 13.15% and a net margin of 41.09%. The business's revenue for the quarter was down 74.1% compared to the same quarter last year. During the same period in the prior year, the company posted $7.04 earnings per share. What ETFs hold BioNTech's stock? ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX) and iShares Biotechnology ETF (IBB). What guidance has BioNTech issued on next quarter's earnings? BioNTech updated its FY 2024 earnings guidance on Tuesday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $4.2 billion. What is Ugur Sahin's approval rating as BioNTech's CEO? 33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD). When did BioNTech IPO? (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.66%), Primecap Management Co. CA (2.00%), Harding Loevner LP (1.66%), Flossbach Von Storch AG (1.49%), Capital World Investors (0.39%) and Voloridge Investment Management LLC (0.25%). How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does BioNTech have any subsidiaries? The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.Read More This page (NASDAQ:BNTX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.